Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? 23 Jul, 2017 | 19:41h | UTC Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? – BMC Medicine (free)